Clinical trial protocol for continuous glucose monitoring in critical care at Hospital Clinic of Barcelona ( CGM ‐ UCI23 )
Open Access
- 28 October 2024
- journal article
- research article
- Published by Wiley in Nursing in Critical Care
- Vol. 30 (3)
Abstract
Background: Hyperglycaemia is common in intensive care units (ICUs), with a prevalence of up to 86.2%, increasing mortality. Technology has evolved towards continuous glucose monitoring (CGM), and its use in ICUs began especially during the coronavirus pandemic (COVID‐19). Various studies have evaluated the reliability of CGM, indicating that it is safe for use in critically ill patients. Aim: The aim of this study was to compare the use of CGM with point‐of‐care glucose (POC‐G) testing in ICU. Specific objectives include evaluating the glycaemic control, the frequency of POC‐G measurements, the incidence of hyperglycaemia, hypoglycaemia and morbidity and mortality at 90 days. Study Design: An experimental, controlled and randomized clinical trial with a single‐blind design will be conducted at Hospital Clinic of Barcelona (HCB). A sample size of 376 participants will be recruited and randomly assigned to two groups: an experimental group, where glycaemic management will be based on CGM; and a control group, where glucose will be managed through POC‐G testing, with a blinded CGM. Results: The primary variable considered will be time in range (TIR), with secondary outcomes including, time above range (TAR), time below range (TBR), number of POC‐G measurements, incidence of hyperglycaemia and hypoglycaemia, and mortality. Hypothesis testing will use the Kolmogorov–Smirnov test to assess data normality, with appropriate statistical tests applied, considering a p ‐value <.05. Relevance to Clinical Practice: The results obtained will help us understand the impact of CGM on critically ill patients. CGM could potentially reduce the workload of nurses and improve the efficiency of decision‐making by the ICU team, enabling early identification and treatment of glucose complications, thereby enhancing safety. Patient safety, a reduction in patient fingerstick and a decreased care burden are the criteria that add value to this research.Keywords
Funding Information
- Dexcom (HOS‐2023‐021)
This publication has 25 references indexed in Scilit:
- Continuous glucose monitor accuracy during extracorporeal membrane oxygenationCritical Care and Resuscitation, 2023
- Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic KetoacidosisDiabetes Technology & Therapeutics, 2023
- Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care CenterEndocrine Practice, 2022
- Relationship Between Glucose Time in Range in Diabetic and Non-Diabetic Patients and Mortality in Critically Ill PatientsJournal of Intensive Care Medicine, 2022
- Glucose intolerance in intensive care patients: Incidence and outcomeEgyptian Journal of Anaesthesia, 2020
- Use of Continuous Glucose Monitoring to Assess Parenteral Nutrition–Induced Hyperglycemia in an Adult Patient With Severe COVID‐19Journal of Parenteral and Enteral Nutrition, 2020
- Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patientsMedicine, 2018
- Historia y evolución de la medicina crítica: de los cuidados intensivos a la terapia intensiva y cuidados críticosActa Colombiana de Cuidado Intensivo, 2017
- Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 DiabetesJournal of Diabetes Science and Technology, 2016
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsBMJ, 2013